Developer docs
API playgroundTry for free, no card

Search company profiles

Moonwalk Biosciences

Full company profile

uuid0000kp7

Namestring
Moonwalk Biosciences
Legal namestring
Moonwalk Biosciences, Inc.
Websiteurl
moonwalk.bio
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision medicines that target the epigenome — the regulatory layer above DNA — rather than the DNA sequence itself. The company couples two proprietary platforms: EpiRead, which performs whole-genome, high-resolution single-cell mapping of DNA methylation across healthy and diseased cell states, and EpiWrite, a modular non-DNA-cutting toolkit that applies targeted methylation modifications to activate or suppress genes, demonstrated to perform seven simultaneous multiplexed edits at >85% efficiency in primary human cells. An AI layer built around a proprietary Transformer model called Methylencoder, combined with the first genome-wide epigenetic atlas of human adipose tissue, is used to predict and validate novel therapeutic targets.

The company's pipeline comprises seven preclinical candidates (MW01 through MW09) addressing obesity and cardiometabolic disease through adipose-biology mechanisms including lipolysis, thermogenesis, adipogenesis, adipose endocrine function, and energy homeostasis; MW01 is the most advanced in IND-enabling studies with NHP pharmacodynamic data expected in early 2027. In February 2026, the company publicly shifted its lead modality toward siRNA-based obesity therapeutics while retaining its adipose-biology discovery engine and epigenetic expertise.

The business model is licensing- and partnership-oriented: as a private, venture-backed preclinical company Moonwalk has no commercial revenue and no product pricing. It was launched in January 2024 with $57 million in combined seed and Series A financing led by Alpha Wave Ventures with ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The company is co-founded by Feng Zhang (CRISPR pioneer, Broad Institute/MIT), Alex Aravanis (former CTO of Illumina and co-founder of GRAIL), Arash Jamshidi (former SVP Data Sciences at GRAIL), and Justin Valley (former VP at Berkeley Lights), and operates from South San Francisco and San Diego with a headcount in the 11–50 range.

Short descriptiontext

Moonwalk Biosciences is a preclinical biotech developing precision epigenetic medicines for obesity and cardiometabolic disease, coupling its EpiRead methylome-mapping and EpiWrite epigenetic-editing platforms (now pivoting toward siRNA) with an AI-driven adipose-biology discovery engine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic drug discovery, precision epigenetic medicines, cardiometabolic therapeutics, obesity drug pipeline, epigenome engineering platform
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Epigenetic Therapeutics — Cardiometabolic Drug Discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Epigenetic therapeutic pipeline development
TypeLicensing Royalties
Description

As a preclinical stage biotechnology company, Moonwalk Biosciences is in the drug discovery phase with no commercial revenue. The company is developing a pipeline of epigenetic therapeutics for cardiometabolic diseases (obesity, liver disease). Financing has come from venture capital investors including Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures.

moonwalk.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision epigenetic medicines for cardiometabolic diseases, principally obesity and liver disorders. Its core offering is the integrated EpiRead™ epigenetic profiling and EpiWrite™ epigenetic engineering platform, which enables AI-guided target discovery and a pipeline of preclinical drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting adipose biology. The company also recently announced a strategic shift toward siRNA-based obesity therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Seven simultaneous multiplexed edits at >85% efficiency for all seven edits in primary human cells
+1 more record
Product overview1 text field

Moonwalk Biosciences is a preclinical stage biotechnology company pioneering precision epigenetic medicines through its integrated EpiRead™ and EpiWrite™ platform technologies. EpiRead™ provides whole genome, high-resolution single-cell mapping of the methylome, while EpiWrite™ offers targeted methylation modifications through a modular non-DNA cutting toolkit capable of seven simultaneous multiplexed edits. The company leverages AI for epigenetic target prediction and is advancing a pipeline of siRNA-based drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting obesity and cardiometabolic diseases through diverse adipose mechanisms including lipolysis, thermogenesis, adipogenesis, and energy homeostasis.

Product and service9 records
1EpiRead™
CategoryDiscovery platform
Description

Epigenetic profiling platform providing whole-genome, high-resolution single-cell mapping of the methylome, offering the most complete view of the epigenome in health and disease for internal drug discovery use.

2EpiWrite™
CategoryEngineering platform
Description

Epigenetic engineering platform using a modular non-DNA-cutting toolkit for targeted methylation modifications enabling gene activation and suppression, capable of seven simultaneous multiplexed edits at >85% efficiency in primary human cells.

3MW01
CategoryDrug candidate (obesity)
Description

Obesity drug candidate targeting lipolysis and lipid droplet regulation; currently in IND-enabling stage.

4MW02
CategoryDrug candidate (obesity)
Description

Obesity drug candidate targeting thermogenesis and brown/beige pathways; currently in preclinical candidate stage.

5MW03
CategoryDrug candidate (obesity)
Description

Obesity drug candidate targeting adipogenesis and differentiation; currently in preclinical stage.

6MW05
CategoryDrug candidate (lipid lowering)
Description

Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.

7MW08
CategoryDrug candidate (lipid lowering)
Description

Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.

8MW09
CategoryDrug candidate (obesity)
Description

Obesity drug candidate targeting energy homeostasis; currently in discovery stage.

9MWₙ
CategoryDrug candidate (pipeline expansion)
Description

Additional pipeline targets and combinations under testing for obesity and other indications; currently in target validation stage.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Cardiometabolic Advisory Board
Strategic tierCoreTypeOthersAnnounced on2024-08-19
Description

World-class advisory board composed of five leading scientific and clinical experts: Paul Cohen (Rockefeller University), Silvia Corvera (UMass Chan Medical School), Michael Czech (UMass Chan Medical School), Shingo Kajimura (Harvard Medical School, HHMI Investigator), Rohit Loomba (UCSD). They bring expertise in adipocyte and liver biology to guide research programs.

moonwalk.bio
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chroma Medicine is a direct peer developing a single-platform epigenetic editing approach using engineered chromatin regulators and CRISPR-derived systems to tune gene expression without altering DNA sequence. Highly comparable to Moonwalk's EpiWrite platform, both targeting the same epigenetic medicines opportunity.

TypeDirect peer
Description

Tune Therapeutics is a direct peer pioneering epigenetic gene silencing and programming using a single-platform approach. Highly comparable to Moonwalk's epigenetic editing vision and competes in the same target space of durable, non-DNA-altering gene regulation.

TypeEmerging player
Description

Epicypher develops chromatin/epigenomics research tools and reagents. While not a therapeutic company, they overlap in epigenetic target ID, mapping, and chromatin biology — capabilities Moonwalk's EpiRead platform also pursues.

TypeDirect peer
Description

Prime Medicine develops prime editing therapies, a next-generation gene editing modality. As a direct peer in the gene/epigenetic editing space with similar founder pedigree (David Liu), they compete for talent, capital, and partnership economics in precision genetic medicines.

TypeDirect peer
Description

Verve Therapeutics is a direct peer pioneering in vivo gene editing for cardiovascular disease, founded out of David Liu's lab. Highly comparable in cardiometabolic disease targeting and the broader precision gene editing platform race.

TypeDirect peer
Description

Beam Therapeutics is a direct peer in precision genetic medicines, founded by Feng Zhang, David Liu, and Jinke Cheng. Beam is also co-founded by Moonwalk's scientific co-founder Feng Zhang, making it both a peer and a portfolio-overlap reference for Moonwalk's investor base.

TypeBroad incumbent
Description

Alnylam is the established leader in RNAi/siRNA therapeutics. Following Moonwalk's Feb 2026 pivot to siRNA obesity therapies, Alnylam is the most relevant reference for the modality's clinical validation, delivery technology (GalNAc), and partnership economics.

TypeBroad incumbent
Description

Arrowhead is an established siRNA therapeutics company with a broad pipeline including cardiometabolic and liver-targeted programs. Following Moonwalk's pivot, Arrowhead is a key reference for siRNA-based obesity and liver disease development.

TypeEmerging player
Description

Korro Bio is an emerging player in RNA editing for genetic diseases, sharing Moonwalk's precision nucleic acid approach and operating with a similar early-stage platform-to-pipeline model. Comparable in stage, technology paradigm, and target ambition.

TypeEmerging player
Description

Metagenomi is an emerging precision gene editing company developing a broad toolbox of editing modalities (CRISPR-derived and novel). Comparable as a platform-to-pipeline biotech in the broader genetic medicines space where Moonwalk operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moonwalk Biosciences

Epigenetic Therapeutics — Cardiometabolic Drug Discoverymoonwalk.bio

Moonwalk Biosciences is a preclinical biotech developing precision epigenetic medicines for obesity and cardiometabolic disease, coupling its EpiRead methylome-mapping and EpiWrite epigenetic-editing platforms (now pivoting toward siRNA) with an AI-driven adipose-biology discovery engine.

What Moonwalk Biosciences does

Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision medicines that target the epigenome — the regulatory layer above DNA — rather than the DNA sequence itself. The company couples two proprietary platforms: EpiRead, which performs whole-genome, high-resolution single-cell mapping of DNA methylation across healthy and diseased cell states, and EpiWrite, a modular non-DNA-cutting toolkit that applies targeted methylation modifications to activate or suppress genes, demonstrated to perform seven simultaneous multiplexed edits at >85% efficiency in primary human cells. An AI layer built around a proprietary Transformer model called Methylencoder, combined with the first genome-wide epigenetic atlas of human adipose tissue, is used to predict and validate novel therapeutic targets.

The company's pipeline comprises seven preclinical candidates (MW01 through MW09) addressing obesity and cardiometabolic disease through adipose-biology mechanisms including lipolysis, thermogenesis, adipogenesis, adipose endocrine function, and energy homeostasis; MW01 is the most advanced in IND-enabling studies with NHP pharmacodynamic data expected in early 2027. In February 2026, the company publicly shifted its lead modality toward siRNA-based obesity therapeutics while retaining its adipose-biology discovery engine and epigenetic expertise.

The business model is licensing- and partnership-oriented: as a private, venture-backed preclinical company Moonwalk has no commercial revenue and no product pricing. It was launched in January 2024 with $57 million in combined seed and Series A financing led by Alpha Wave Ventures with ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The company is co-founded by Feng Zhang (CRISPR pioneer, Broad Institute/MIT), Alex Aravanis (former CTO of Illumina and co-founder of GRAIL), Arash Jamshidi (former SVP Data Sciences at GRAIL), and Justin Valley (former VP at Berkeley Lights), and operates from South San Francisco and San Diego with a headcount in the 11–50 range.

Moonwalk Biosciences firmographics

Firmographics
Name
Moonwalk Biosciences
Legal name
Moonwalk Biosciences, Inc.
Website
https://moonwalk.bio
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Moonwalk Biosciences is a preclinical biotech developing precision epigenetic medicines for obesity and cardiometabolic disease, coupling its EpiRead methylome-mapping and EpiWrite epigenetic-editing platforms (now pivoting toward siRNA) with an AI-driven adipose-biology discovery engine.
Ownership category
akta.pro rank

Moonwalk Biosciences industry classification

Industry
Product category
Epigenetic Therapeutics — Cardiometabolic Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Epigenetic drug discovery
  • Precision epigenetic medicines
  • Cardiometabolic therapeutics
  • Obesity drug pipeline
  • Epigenome engineering platform

Where Moonwalk Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Moonwalk Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Epigenetic therapeutic pipeline development: As a preclinical stage biotechnology company, Moonwalk Biosciences is in the drug discovery phase with no commercial revenue. The company is developing a pipeline of epigenetic therapeutics for cardiometabolic diseases (obesity, liver disease). Financing has come from venture capital investors including Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Moonwalk Biosciences product offering

Product offering

Core offering

Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision epigenetic medicines for cardiometabolic diseases, principally obesity and liver disorders. Its core offering is the integrated EpiRead™ epigenetic profiling and EpiWrite™ epigenetic engineering platform, which enables AI-guided target discovery and a pipeline of preclinical drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting adipose biology. The company also recently announced a strategic shift toward siRNA-based obesity therapeutics.

Product overview

Moonwalk Biosciences is a preclinical stage biotechnology company pioneering precision epigenetic medicines through its integrated EpiRead™ and EpiWrite™ platform technologies. EpiRead™ provides whole genome, high-resolution single-cell mapping of the methylome, while EpiWrite™ offers targeted methylation modifications through a modular non-DNA cutting toolkit capable of seven simultaneous multiplexed edits. The company leverages AI for epigenetic target prediction and is advancing a pipeline of siRNA-based drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting obesity and cardiometabolic diseases through diverse adipose mechanisms including lipolysis, thermogenesis, adipogenesis, and energy homeostasis.

Differentiator

Problem solved

Functional benefit

Products and services

  • EpiRead™ Epigenetic profiling platform providing whole-genome, high-resolution single-cell mapping of the methylome, offering the most complete view of the epigenome in health and disease for internal drug discovery use.
  • EpiWrite™ Epigenetic engineering platform using a modular non-DNA-cutting toolkit for targeted methylation modifications enabling gene activation and suppression, capable of seven simultaneous multiplexed edits at >85% efficiency in primary human cells.
  • MW01 Obesity drug candidate targeting lipolysis and lipid droplet regulation; currently in IND-enabling stage.
  • MW02 Obesity drug candidate targeting thermogenesis and brown/beige pathways; currently in preclinical candidate stage.
  • MW03 Obesity drug candidate targeting adipogenesis and differentiation; currently in preclinical stage.
  • MW05 Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.
  • MW08 Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.
  • MW09 Obesity drug candidate targeting energy homeostasis; currently in discovery stage.
  • MWₙ Additional pipeline targets and combinations under testing for obesity and other indications; currently in target validation stage.

Quantifiable outcome

  • Seven simultaneous multiplexed edits at >85% efficiency for all seven edits in primary human cells
  • +1 more outcomes

Companies that use Moonwalk Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Moonwalk Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Moonwalk Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cardiometabolic Advisory BoardcoreOthers · 19 August 2024World-class advisory board composed of five leading scientific and clinical experts: Paul Cohen (Rockefeller University), Silvia Corvera (UMass Chan Medical School), Michael Czech (UMass Chan Medical School), Shingo Kajimura (Harvard Medical School, HHMI Investigator), Rohit Loomba (UCSD). They bring expertise in adipocyte and liver biology to guide research programs.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Moonwalk Biosciences competitors and assessment

Company assessment

Direct peers

  • Chroma Medicine: Chroma Medicine is a direct peer developing a single-platform epigenetic editing approach using engineered chromatin regulators and CRISPR-derived systems to tune gene expression without altering DNA sequence. Highly comparable to Moonwalk's EpiWrite platform, both targeting the same epigenetic medicines opportunity.
  • Tune Therapeutics: Tune Therapeutics is a direct peer pioneering epigenetic gene silencing and programming using a single-platform approach. Highly comparable to Moonwalk's epigenetic editing vision and competes in the same target space of durable, non-DNA-altering gene regulation.
  • Prime Medicine: Prime Medicine develops prime editing therapies, a next-generation gene editing modality. As a direct peer in the gene/epigenetic editing space with similar founder pedigree (David Liu), they compete for talent, capital, and partnership economics in precision genetic medicines.
  • Verve Therapeutics: Verve Therapeutics is a direct peer pioneering in vivo gene editing for cardiovascular disease, founded out of David Liu's lab. Highly comparable in cardiometabolic disease targeting and the broader precision gene editing platform race.
  • Beam Therapeutics: Beam Therapeutics is a direct peer in precision genetic medicines, founded by Feng Zhang, David Liu, and Jinke Cheng. Beam is also co-founded by Moonwalk's scientific co-founder Feng Zhang, making it both a peer and a portfolio-overlap reference for Moonwalk's investor base.

Emerging players

  • Epicypher: Epicypher develops chromatin/epigenomics research tools and reagents. While not a therapeutic company, they overlap in epigenetic target ID, mapping, and chromatin biology — capabilities Moonwalk's EpiRead platform also pursues.
  • Korro Bio: Korro Bio is an emerging player in RNA editing for genetic diseases, sharing Moonwalk's precision nucleic acid approach and operating with a similar early-stage platform-to-pipeline model. Comparable in stage, technology paradigm, and target ambition.
  • Metagenomi: Metagenomi is an emerging precision gene editing company developing a broad toolbox of editing modalities (CRISPR-derived and novel). Comparable as a platform-to-pipeline biotech in the broader genetic medicines space where Moonwalk operates.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the established leader in RNAi/siRNA therapeutics. Following Moonwalk's Feb 2026 pivot to siRNA obesity therapies, Alnylam is the most relevant reference for the modality's clinical validation, delivery technology (GalNAc), and partnership economics.
  • Arrowhead Pharmaceuticals: Arrowhead is an established siRNA therapeutics company with a broad pipeline including cardiometabolic and liver-targeted programs. Following Moonwalk's pivot, Arrowhead is a key reference for siRNA-based obesity and liver disease development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Moonwalk Biosciences social profiles

Digital presence

Moonwalk Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moonwalk Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Moonwalk Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moonwalk Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moonwalk Biosciences

What does Moonwalk Biosciences do?

Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision epigenetic medicines for cardiometabolic diseases, principally obesity and liver disorders. Its core offering is the integrated EpiRead™ epigenetic profiling and EpiWrite™ epigenetic engineering platform, which enables AI-guided target discovery and a pipeline of preclinical drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting adipose biology. The company also recently announced a strategic shift toward siRNA-based obesity therapeutics.

Is Moonwalk Biosciences a public or private company?

Moonwalk Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Moonwalk Biosciences founded?

Moonwalk Biosciences was founded in 2024. It employs 11 to 50 people.

Where is Moonwalk Biosciences based?

Moonwalk Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Moonwalk Biosciences make money?

One revenue line is on record: epigenetic therapeutic pipeline development.

Who are Moonwalk Biosciences's main competitors?

Direct peers on record are Chroma Medicine, Tune Therapeutics, Prime Medicine, Verve Therapeutics and Beam Therapeutics. Emerging players are Epicypher, Korro Bio and Metagenomi. Broad incumbents are Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals.

Does Moonwalk Biosciences have an API?

No public API is recorded for Moonwalk Biosciences.

What industry is Moonwalk Biosciences in?

Moonwalk Biosciences's product category is Epigenetic Therapeutics — Cardiometabolic Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaMoonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic DiseasesMoonwalk Biosciences closed a $70 million Series B financing co-led by Alpha Wave and YK Bioventures. Proceeds will advance its lead obesity candidate MW101 into first-in-human studies in late 2027. The company also plans to expand its pipeline of tissue-targeted siRNA medicines.pharmaphorumEncoded raises $275m for Dravet therapy and other financingsEncoded Therapeutics raised $275 million to advance its Dravet syndrome gene therapy ETX101 into a pivotal trial, following phase 1/2 POLARIS data showing reduced seizure frequency. The funding will also support manufacturing scale-up and development of a second drug candidate, ETX301, for post-amputation pain.Longevity.TechnologyMoonwalk raises $70m for adipose-targeted RNAiMoonwalk Biosciences raised $70M in a Series B led by Alpha Wave and YK Bioventures to advance its adipose-targeted RNAi therapy MW101. The company plans first-in-human studies in late 2027, aiming to reduce fat mass while preserving lean mass without suppressing appetite. The therapy's delivery technology is a key differentiator.citybizMoonwalk Biosciences Secures $70M Series B Co-Led by Alpha Wave, YK VenturesMoonwalk Biosciences closed a $70 million Series B co-led by Alpha Wave and YK Ventures. Proceeds will advance its lead obesity candidate MW101 into first-in-human trials in late 2027 and expand its siRNA pipeline. The company targets adipose tissue with RNAi, differing from Ozempic-type drugs.Longevity.TechnologyMoonwalk Biosciences raises $70m to test new muscle-sparing obesity drug in humansMoonwalk Biosciences closed a $70 million Series B co-led by Alpha Wave and YK Bioventures, with Eli Lilly and others participating. The funds will advance its obesity drug MW101 into first-in-human studies in late 2027 and expand its adipose-selective siRNA pipeline.FortuneThey built exoskeletons for stroke patients. Now, their robots can do eyelash extensionsLuum, a startup that built exoskeletons for stroke patients, now offers a robot for eyelash extensions. The company has raised $36 million and plans to cut appointment times to about 30 minutes. It aims to expand into other beauty services like eyebrow threading and microneedling.Pulse 2.0Moonwalk Biosciences Raises $70 Million Series B To Advance Adipose-Targeted RNAi Obesity TherapiesMoonwalk Biosciences has raised an oversubscribed $70 million Series B financing led by Alpha Wave and YK Bioventures to advance its pipeline of adipose-targeted RNA interference medicines for obesity. The company plans to use the funds to move its lead candidate, MW101, into first-in-human clinical studies scheduled for late 2027 while expanding its tissue-targeted siRNA programs. Additionally, Moonwalk appointed Dr. Stephen Djedjos as Senior Vice President of Clinical Development to support these efforts.BioPharma DiveMoonwalk reloads with $70M and new RNAi prospects for obesityMoonwalk Biosciences raised $70 million in a Series B round to develop RNA interference treatments for obesity. The company plans to enter human testing for its lead drug, MW101, by the end of 2027. It aims to avoid gastrointestinal side effects of GLP-1 drugs by modulating fat metabolism.BioSpaceMoonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinicMoonwalk Biosciences raised $70 million in a Series B round to advance its RNAi-based obesity drug MW101 to first-in-human trials in late 2027. Preclinical studies showed weight loss and fat reduction while preserving muscle mass. The company plans to use the funds to support clinical development.Endpoints NewsMoonwalk raises $70M to test siRNA treatment for obesityMoonwalk Biosciences raised $70 million to test an siRNA treatment for obesity. The company is heading to the clinic with an obesity program, leveraging a shift in its strategy.